Diabetes, Higher BMI Identified as Risk Factors for RCC Upstaging
In a study, diabetes increased the odds of pathologic upgrading of renal cell carcinoma by 65% and 32%, among patients undergoing partial and radical nephrectomy, respectively.
In a study, diabetes increased the odds of pathologic upgrading of renal cell carcinoma by 65% and 32%, among patients undergoing partial and radical nephrectomy, respectively.
A retrospective study revealed no significant difference in 36-month progression-free survival and renal function outcomes in patients with small renal masses.
Cancer death rates have declined in the United States in recent years, but the declines are greater in urban than in rural areas, data suggest.
Investigators believe their study is the first to demonstrate the adverse impact of LVI on overall survival in patients with surgically treated renal cell carcinoma.
In a study, the Selection for Cytoreductive Nephrectomy (SCREEN) score demonstrated superiority in predicting first-year mortality among patients with metastatic kidney cancer compared with an IMDC model.
The Kidney Cancer Risk Equation for predicting post-nephrectomy ESKD builds on the ubiquitous Kidney Failure Risk Equation and is easy to use, according to investigators.
At ASCO 2023, investigators reported results from phase 3 trials that could improve therapeutic approaches to bladder, prostate, and kidney cancer.
Relapse-free survival should not be used as a surrogate for overall survival in cancer trials testing adjuvant immunotherapy, according to researchers.
Adding stereotactic body radiation therapy to immune checkpoint inhibitor therapy was safe but failed to improve progression-free and overall survival.
An analysis of groundwater revealed 7 constituents — such as chlordane, dieldrin, and glyphosphate — that may increase the risk of kidney cancer.